Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration

Eye Diseases Prevalence Research Group, 2004, Causes and prevalence of visual impairment among adults in the United States, Arch Ophthalmol, 122, 477, 10.1001/archopht.122.4.477

Brown, 2006, Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N Engl J Med, 355, 1432, 10.1056/NEJMoa062655

Rosenfeld, 2006, Ranibizumab for neovascular age-related macular degeneration, N Engl J Med, 355, 1419, 10.1056/NEJMoa054481

Bressler, 2011, Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration, Arch Ophthalmol, 129, 709, 10.1001/archophthalmol.2011.140

Cohen, 2009, Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting, Am J Ophthalmol, 148, 409, 10.1016/j.ajo.2009.04.001

Dadgostar, 2009, Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration, Ophthalmology, 116, 1740, 10.1016/j.ophtha.2009.05.033

Regillo, 2008, Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1, Am J Ophthalmol, 145, 239, 10.1016/j.ajo.2007.10.004

Schmidt-Erfurth, 2011, Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study, Ophthalmology, 118, 831, 10.1016/j.ophtha.2010.09.004

Lalwani, 2009, A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study, Am J Ophthalmol, 148, 43, 10.1016/j.ajo.2009.01.024

Singer, 2012, HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration, Ophthalmology, 119, 1175, 10.1016/j.ophtha.2011.12.016

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, 2012, Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results, Ophthalmology, 119, 1388, 10.1016/j.ophtha.2012.03.053

CATT Research Group, 2011, Ranibizumab and bevacizumab for neovascular age-related macular degeneration, N Engl J Med, 364, 1897, 10.1056/NEJMoa1102673

Papadopoulos, 2012, Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab, Angiogenesis, 15, 171, 10.1007/s10456-011-9249-6

Holash, 2002, VEGF-Trap: a VEGF blocker with potent antitumor effects, Proc Natl Acad Sci U S A, 99, 11393, 10.1073/pnas.172398299

Stewart, 2012, Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye), Retina, 32, 434

Heier, 2012, Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration, Ophthalmology, 119, 2537, 10.1016/j.ophtha.2012.09.006

Engelbert, 2010, Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy, Retina, 30, 1368, 10.1097/IAE.0b013e3181d50cbf

Gupta, 2010, A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact, Ophthalmology, 117, 2134, 10.1016/j.ophtha.2010.02.032